|
KMID : 1140120090140010020
|
|
Cancer Prevention Research
2009 Volume.14 No. 1 p.20 ~ p.27
|
|
|
Effects of Tamoxifen and Ghrelin in ER-positive MCF-7 and ER-negative MDA-MB231 Breast Cancer Cells
|
|
Baik Hyung-Hwan
Choe Won-Chae
|
|
|
Abstract
|
|
|
|
Tamoxifen (Tam) is widely used in chemotherapy of breast cancer. It inhibits proliferation and induces apoptosis of breast cancer cells by estrogen receptor (ER)-dependent modulation of gene expression. ER involves with AMPK and MAPK pathway. Ghrelin is growth hormone and binds to growth hormone secreatagogue receptor1 (GHSR-1) that have estrogen receptor similar pathway. We studied to Tamoxifen, Estadiol & Ghrelin effects by MTT assay for cell viability and western blot for ERK/p38 phosphorylation in ER-positive MCF-7 (ER＋) and ER-negative MDA-MB231 (ER?). We showed to MCF-7 cell death induction by Tamoxifen dose-dependent manner. But we can see inhibition of Tamoxifen effect by Estradiol and Ghrelin. ERK phosphorylation increased 2.9∼18.5-fold by dose-dependent Tamoxifen in both ER＋ MCF-7 cells and 7.8-fold by 7μM Tamoxifen treatment in ER? MDA-MB231 cells. ERK phosphorylation was induced by Estadiol and Ghrelin in only ER＋ MCF-7 cells, but p38 phosphorylation was not affected by Estradiol, Ghrelin and Tamoxifen in breast cancer cells. In conclusion, ERK activation of MAPK by Tamoxifen for cell death and Ghrelin in ER-positive MCF-7 cell line was observed.
|
|
|
KEYWORD
|
|
|
MCF7, MDA-MB231, Breast cancer, Tamoxifen, Ghrelin, Estrogen receptor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|